Lipella Pharmaceuticals Files 8-K: Material Agreement & Equity Sales
Ticker: LIPO · Form: 8-K · Filed: Dec 10, 2024 · CIK: 1347242
| Field | Detail |
|---|---|
| Company | Lipella Pharmaceuticals Inc. (LIPO) |
| Form Type | 8-K |
| Filed Date | Dec 10, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.0001, $6,000,000, $1.00, $300,000, $200,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
TL;DR
Lipella Pharma signed a big deal & sold stock, filing details today.
AI Summary
On December 5, 2024, Lipella Pharmaceuticals Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company also reported on unregistered sales of equity securities and filed financial statements and exhibits. The filing was made on December 10, 2024.
Why It Matters
This 8-K filing indicates significant corporate activity for Lipella Pharmaceuticals, including a new material agreement and equity transactions, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing mentions a material definitive agreement and unregistered sales of equity, which can introduce financial and operational risks if not managed properly.
Key Players & Entities
- Lipella Pharmaceuticals Inc. (company) — Registrant
- December 5, 2024 (date) — Earliest event reported
- December 10, 2024 (date) — Filing date
- Pittsburgh, PA (location) — Principal executive office location
FAQ
What is the nature of the material definitive agreement entered into by Lipella Pharmaceuticals?
The filing states that Lipella Pharmaceuticals Inc. entered into a material definitive agreement on December 5, 2024, but the specific terms and counterparty are not detailed in this 8-K.
What type of equity securities were sold by Lipella Pharmaceuticals?
The filing indicates 'Unregistered Sales of Equity Securities' occurred, but the specific type and amount of securities are not disclosed in this document.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted to the SEC on December 10, 2024.
Where is Lipella Pharmaceuticals Inc. headquartered?
Lipella Pharmaceuticals Inc.'s principal executive office is located at 7800 Susquehanna St., Suite 505, Pittsburgh, PA 15208.
What are the main items reported in this 8-K filing?
This 8-K filing reports on the 'Entry into a Material Definitive Agreement', 'Unregistered Sales of Equity Securities', and 'Financial Statements and Exhibits'.
Filing Stats: 1,487 words · 6 min read · ~5 pages · Grade level 14.1 · Accepted 2024-12-10 09:29:44
Key Financial Figures
- $0.0001 — registered Common Stock, par value $0.0001 per share LIPO The Nasdaq Stock Mar
- $6,000,000 — ffer and sale (the "Offering") of up to $6,000,000 of Series B non-voting convertible pref
- $1.00 — suance, shall have an exercise price of $1.00 per share and shall contain provisions
- $300,000 — pany shall pay to Spartan a cash fee of $300,000, which amount shall be paid out of the
- $200,000 — pany shall pay to Spartan a cash fee of $200,000, which shall be paid on a pro rata basi
Filing Documents
- g084587_8k.htm (8-K) — 45KB
- g084587_ex10-1.htm (EX-10.1) — 133KB
- g084587_ex10-2.htm (EX-10.2) — 56KB
- g084587_ex10-3.htm (EX-10.3) — 17KB
- 0001753926-24-002052.txt ( ) — 473KB
- lipo-20241205.xsd (EX-101.SCH) — 3KB
- lipo-20241205_lab.xml (EX-101.LAB) — 33KB
- lipo-20241205_pre.xml (EX-101.PRE) — 22KB
- g084587_8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 10, 2024 Lipella Pharmaceuticals Inc. By: /s/ Jonathan Kaufman Name: Jonathan Kaufman Title: Chief Executive Officer